Several studies have examined PD-L1 expression between a primary NSCLC and its metastases [[27], [28], [29]] and, though approaches and methodologies differ, the general consensus of these is that expression of PD-L1 varies between tumour sites in the majority of cases. This evidence concerns the gene CD274 and neoplasm.